In April, the FDA approved regorafenib (Stivarga), a small-molecule multikinase inhibitor, as a second-line treatment for patients with HCC who have previously received sorafenib. The agency is scheduled to decide by September 24 whether to approve a supplemental biologics license application for niv...
The indication for hepatic resection is strictly limited in the most recent BCLC staging updates; inversely, several reports in the literature have promoted its wider application [12,17,46,47]. Large and qualified multicentric surveys have shown that surgery is widely applied in current practice ...